FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma
Simone Lubrano(University of California San Diego), Rodolfo Daniel Cervantes‐Villagrana(University of California San Diego), Farhoud Faraji(UC San Diego Health System), Sydney I. Ramirez(University of California San Diego), Kuniaki Sato(University of California San Diego), Sendi Rafael Adame-Garcia(University of California San Diego), Adam Officer(University of California San Diego), Nadia Arang(QB3), Damiano Cosimo Rigiracciolo(University of California San Diego), Paola Y. Anguiano Quiroz(University of California San Diego), Claudia Martini(University of Pisa), YiYu Wang(University of Montana), Fleur M. Ferguson(University of Montana), Antonietta Bacchiocchi(Yale University), Ruth Halaban(Yale University), Sílvia Coma(Verastem (United States)), Sheri L. Holmen(University of Utah), Jonathan A. Pachter(Verastem (United States)), Andrew E. Aplin(Sidney Kimmel Cancer Center), J. Silvio Gutkind(University of California San Diego)
Cited by 34Open Access
Abstract
Related Papers
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert, Bogusława Karaszewska, Jacob Schachter et al.|New England Journal of Medicine|2014|2.6k